Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
- Astellas Gets Rights to Urology Drug Rosiptor in Asia-Pacific Region
May 11, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- YL Biologics Files Enbrel Biosimilar in Japan
May 11, 2018
- MSD Japan Seeks Adjuvant Melanoma Nod for Keytruda
May 11, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Shire Buyout a Must for Takeda’s Leap in Global Arena: Board Chair
May 10, 2018
- Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
May 10, 2018
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Takeda’s Shire Deal Inspiring for Japan Industry Peers: Mitsubishi Tanabe Chief
May 10, 2018
- Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
- AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
May 10, 2018
- Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
May 10, 2018
- Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
May 9, 2018
- Daiichi Sankyo, Kaketsuken Terminate Vaccine Sales Partnership
May 9, 2018
- US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
May 9, 2018
- Kissei Mulls Over Urief AG Launch
May 9, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…